Positive Findings Published for Provectus Pharmaceuticals' PV-10

Positive research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication, Provectus Pharmaceuticals, Inc. reports . The article, entitled, “Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer,” was authored by Paul Toomey, MD, Krithika Kodumudi, PhD, Amy Weber, Lisa Kuhn, Ellen Moore, Arnod A. Sarnaik, MD and Shari Pilon-Thomas, PhD, all researchers with Moffitt's Immunology Program. The featured work resulted in part from a Provectus-sponsored research program led by Pilon-Thomas.